top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hTRBC1/hTRBC2 mice
Strain Name C57BL/6-Trbc1tm1(TRBC1)BcgenTrbc2tm1(TRBC2)Bcgen/Bcgen Common Name  B-hTRBC1/hTRBC2 mice
Background C57BL/6JNifdc Catalog number 112003
Aliases 
TCRBC1; TCRBC2


Description


  • T cell receptor beta constant 1 is a protein that in humans is encoded by the TRBC1 gene. T cell receptor beta constant 2 is a protein that in humans is encoded by the TRBC2 gene.
  • The exon1~2, partial exon 3 and intron 1~2 of mouse Trbc1 and Trbc2 were replaced by human The exon1~2, partial exon 3 and intron 1~2 of human TRBC1 and TRBC2 in B-hTRBC1/hTRBC2 mice. 
  • Human TRBC1 was detectable in T cells, but not NK cells or B cells of homozygous B-hTRBC1/hTRBC2 mice. 
  • Humanization of TRBC1 and TRBC2 do not change the overall frequency or distribution of immune cell types in spleen, blood and lymph nodes. 
  • T cells from WT and homozygous mice were successfully activated with anti-mCD3E antibody after 24 hours, and T cells from homozygous mice, but not from WT mice, were activated with anti-human TRBC1 antibody after 24 hours.
  • Application: For example, this product is used for pharmacodynamics and safety evaluation of cancer and  autoimmune diseases such as Islet allograft rejection.


mRNA expression analysis in humanized B-hTRBC1/hTRBC2 mice

from clipboard


Species specific analysis of TRBC1 and TRBC2 gene expression in wild-type C57BL/6 mice and homozygous humanized B-hTRBC1/hTRBC2 mice by RT-PCR. Splenocytes were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hTRBC1/hTRBC2 mice (H/H). Mouse TRBC1 and TRBC2 mRNA were detectable only in wild-type C57BL/6 mice. Human TRBC1 and TRBC2 mRNA were detectable only in homozygous B-hTRBC1/hTRBC2 mice, but not in wild-type C57BL/6 mice. 

Protein expression analysis in spleen B, NK and T cells

from clipboard

Strain specific TRBC1 expression analysis in wild-type C57BL/6 mice and homozygous humanized B-hTRBC1/hTRBC2 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hTRBC1/hTRBC2 mice (H/H), and analyzed with anti-human TRBC1 antibody (Biolegend,383502) by flow cytometry. Human TRBC1 was not detectable in wild-type C57BL/6 mice. Human TRBC1 was exclusively detectable in homozygous B-hTRBC1/hTRBC2 mice.

T cell activation analysis-CD69 and CD25

from clipboard

Activation of T cells was induced with human TRBC1 antibody and mouse CD3E/28 antibodies in wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice. Splenocytes were collected from wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice (H/H, 6-week-old, female, n=3) and purified for pan T cells using mouse Pan T Cell Isolation Kit II (Miltenyi Biotec, 130-095-130). Pan T cells were respectively stimulated with anti-mouse CD3E (BioXcell, BE0001-1), anti-mouse CD28 (BioXcell, BE0015-1) and human TRBC1 (Biolegend, 383502) antibodies for 24 hours in vivo. Activation of T cells was analyzed with anti-mouse CD69 (Biolegend, 104514) (A) and CD25 (Biolegend, 102008) (B) antibodies. T cells from WT and homozygous mice were successfully activated with anti-mCD3E antibody after 24 hours, and T cells from homozygous mice, but not from WT mice, were activated with anti-human TRBC1 antibody after 24 hours.

from clipboard

Activation of T cells was induced with human TRBC1 antibody and mouse CD3E/28 antibodies in wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice. Splenocytes were collected from wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice (H/H, 6-week-old, female, n=3) and purified for pan T cells using mouse Pan T Cell Isolation Kit II (Miltenyi Biotec, 130-095-130). Pan T cells were respectively stimulated with anti-mouse CD3E (BioXcell, BE0001-1), anti-mouse CD28 (BioXcell, BE0015-1) and human TRBC1 (Biolegend, 383502) antibodies for 24 hours in vivo. Activation of T cells was analyzed with anti-mouse CD69 (Biolegend, 104514) (A) and CD25 (Biolegend, 102008) (B) antibodies. T cells from WT and homozygous mice were successfully activated with anti-mCD3E antibody after 24 hours, and T cells from homozygous mice, but not from WT mice, were activated with anti-human TRBC1 antibody after 24 hours.

T cell activation analysis-CD69 and CD25

from clipboard

Activation of T cells was induced with human TRBC1 antibody and mouse CD3E/28 antibodies in wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice. Splenocytes were collected from wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice (H/H;H/H, 6-week-old, female, n=3) and purified for pan T cells using mouse Pan T Cell Isolation Kit II (Miltenyi Biotec, 130-095-130). Pan T cells were respectively stimulated with anti-mouse CD3E (BioXcell, BE0001-1), anti-mouse CD28 (BioXcell, BE0015-1) and human TRBC1 (Biolegend, 383502) antibodies for 24 hours in vivo. Activation of T cells was analyzed with anti-mouse CD69 (Biolegend, 104514) (A) and CD25 (Biolegend, 102008) (B) antibodies. T cells from WT and homozygous mice were successfully activated with anti-mCD3E antibody after 24 hours, and T cells from homozygous mice, but not from WT mice, were activated with anti-human TRBC1 antibody after 24 hours.

from clipboard

Activation of T cells was induced with human TRBC1 antibody and mouse CD3E/28 antibodies in wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice. Splenocytes were collected from wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice (H/H;H/H, 6-week-old, female, n=3) and purified for pan T cells using mouse Pan T Cell Isolation Kit II (Miltenyi Biotec, 130-095-130). Pan T cells were respectively stimulated with anti-mouse CD3E (BioXcell, BE0001-1), anti-mouse CD28 (BioXcell, BE0015-1) and human TRBC1 (Biolegend, 383502) antibodies for 24 hours in vivo. Activation of T cells was analyzed with anti-mouse CD69 (Biolegend, 104514) (A) and CD25 (Biolegend, 102008) (B) antibodies. T cells from WT and homozygous mice were successfully activated with anti-mCD3E antibody after 24 hours, and T cells from homozygous mice, but not from WT mice, were activated with anti-human TRBC1 antibody after 24 hours.

from clipboard

Activation of T cells was induced with human TRBC1 antibody and mouse CD3E/28 antibodies in wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice. Splenocytes were collected from wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice (H/H;H/H, 6-week-old, female, n=3) and purified for pan T cells using mouse Pan T Cell Isolation Kit II (Miltenyi Biotec, 130-095-130). Pan T cells were respectively stimulated with anti-mouse CD3E (BioXcell, BE0001-1), anti-mouse CD28 (BioXcell, BE0015-1) and human TRBC1 (Biolegend, 383502) antibodies for 24 hours in vivo. Activation of T cells was analyzed with anti-mouse CD69 (Biolegend, 104514) (A) and CD25 (Biolegend, 102008) (B) antibodies. T cells from WT and homozygous mice were successfully activated with anti-mCD3E antibody after 24 hours, and T cells from homozygous mice, but not from WT mice, were activated with anti-human TRBC1 antibody after 24 hours.

Human CD3+ T cell activation analysis-hCD69

from clipboard

Activation of human T cells was induced with human CD3E antibody and human TRBC1 antibodies in purified human CD3+ T cells. Human CD3+ T cells were respectively stimulated with anti-human CD3E (BioXcell, BE0001-2) and human TRBC1 (Biolegend, 383502) antibodies for 24 hours in vivo. Activation of T cells was analyzed with anti-human CD69 (Biolegend, 310912) antibody. Human T cells were successfully activated with anti-hCD3E and anti-hTRBC1 antibodies after 42 hours.

Human CD3+ T cell activation analysis-hCD25

from clipboard

Activation of human T cells was induced with human CD3E antibody and human TRBC1 antibodies in purified human CD3+ T cells. Human CD3+ T cells were respectively stimulated with anti-human CD3E (BioXcell, BE0001-2) and human TRBC1 (Biolegend, 383502) antibodies for 24 hours in vivo. Activation of T cells was analyzed with anti-human CD25 (Biolegend, 302610) antibody. Human T cells were successfully activated with anti-hCD3E and anti-hTRBC1 antibodies after 42 hours.

Frequency of leukocyte subpopulations in spleen

from clipboard

Frequency of leukocyte subpopulations in spleen by flow cytometry. Splenocytes were isolated from wild-type C57BL/6 mice and homozygous B-hTRBC1/hTRBC2 mice (n=3, 7-week-old). A. Flow cytometry analysis of the splenocytes was performed to assess the frequency of leukocyte subpopulations. B. Frequency of T cell subpopulations. Percentages of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes, macrophages, CD4+ T cells, CD8+ T cells and Tregs in B-hTRBC1/hTRBC2 mice were similar to those in C57BL/6 mice, demonstrating that humanization of TRBC1 and TRBC2 do not change the frequency or distribution of these cell types in spleen. The frequency of leukocyte subpopulations in blood and lymph node of B-hTRBC1/hTRBC2 mice were also comparable to wild-type C57BL/6 mice (Data not shown). Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test.  *P < 0.05, **P < 0.01, ***p < 0.001.